Fundraising FoxVitruvias Therapeutics
Auburn, US · Founded 2013 · Delaware corporation
Find your way into Vitruvias Therapeutics
234 people in our graph share verified history with the Vitruvias Therapeutics team — schools, employers, funds. One of them is your warm intro.
Wade Armstrongunlockedknows Roger D Graben · together at Auburn University (overlapped)
×8knows the team · via Auburn University
×3knows the team · via Florida State University
Vitruvias Therapeutics was a pharmaceutical company; it has ceased operations, and its products are now owned and/or distributed by H2-Pharma LLC.
Founders & leadership
BM
Bryce M HarveyExecutiveBryce M Harvey has over 30 years of pharmaceutical industry experience spanning retail sales, drug wholesaling, and major pharmaceutical companies, including 22 years with Johnson and Johnson. He founded and led Midlothian Laboratories as president from 2003 to 2012, established H2 Pharma in 2014, and was co-founder of Vitruvias Therapeutics.
RD
Roger D GrabenVice President, Commercial Operations & Quality Assurance2016–2018Executive officer at Vitruvias Therapeutics, a pharmaceutical company now defunct; holds a Ph.D. in pharmaceutics and is a registered pharmacist with experience across corporate management, operations, business development, supply chain, quality management, pharmaceutical manufacturing, and dosage form development.
CL
Carl L WhatleyExecutiveCarl L Whatley was an Executive Officer and Director at Vitruvias Therapeutics, a pharmaceutical company that developed generic products.
CL
Carl Leo Whatley, Jr.General Manager
Board
JW
Jason WildBoard director
MA
Michael AltmanBoard director
ES
Edward SchutterBoard director
Reported raises · per SEC filings
Form D private placements$11.7M disclosed across 2 rounds · 2014–2017
▶$11.5MraisedJan 2018 · 23 investors · PharmaceuticalsRule 506(b)
▶$11.5MraisedJan 2018 · 23 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Bryce M HarveyExecutive Officer, Director
- Jason WildDirector
- Roger D GrabenExecutive Officer
- Michael AltmanDirector
- Edward SchutterDirector
- Carl L WhatleyExecutive Officer, Director
- Offering amount
- $11.5M
- Amount sold
- $11.5M
- Minimum investment
- $25K
- Proceeds to insiders
- $1.5M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$200KraisedJul 2014 · 2 investors · PharmaceuticalsRule 506(b)
▶$200KraisedJul 2014 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carl Leo Whatley, Jr.Executive Officer
- Bryce M HarveyExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $200K
- Minimum investment
- $25K
- Proceeds to insiders
- $595K
- First sale
- Jul 2014
- Incorporated
- Limited Liability Company, Delaware, 2013
- Federal exemptions
- 05, 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Medscape32 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Walgreens25 shared keywordsWalgreens operates a pharmacy and retail health and wellness business, offering prescription services, over-the-counter medications, health products, and photo services to consumers.
1Mg23 shared keywordsThis is a product listing page on an online pharmacy for Tugain Twins 5 Solution, a topical minoxidil-based medicine sold to treat hair loss and promote hair regrowth. The page provides usage instructions, benefits, side effects, and purchase/return details rather than describing a company.
Companies competing with Vitruvias Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Vitruvias Therapeutics do?
- Vitruvias Therapeutics was a pharmaceutical company; it has ceased operations, and its products are now owned and/or distributed by H2-Pharma LLC.
- How much funding has Vitruvias Therapeutics raised?
- Vitruvias Therapeutics has disclosed $11.7M raised across 2 rounds.
- Where is Vitruvias Therapeutics headquartered?
- Vitruvias Therapeutics is headquartered in Auburn, US.